PaxMedica files Nasdaq delisting appeal notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2024
0mins
Should l Buy ?
Source: SeekingAlpha
- PaxMedica Appeals Delisting: PaxMedica has filed an appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq hearings panel to delist the company.
- Reason for Appeal: The company believes that crucial aspects of its recent achievements and ongoing actions to regain compliance were not adequately considered by the hearings panel.
- Market Reaction: PaxMedica shares surged 125% in after-market trading following the news of the appeal.
- Further Information: Seeking Alpha's Quant Rating on PaxMedica, historical earnings data, and financial information are available for those interested in more details about the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
